Efficacy of Osimertinib in Patients With Postoperative Recurrent Non–Small‐Cell Lung Cancer Harboring Sensitizing EGFR Mutations

ABSTRACT Background The efficacy of osimertinib in patients with postoperative recurrent non–small‐cell lung cancer (NSCLC) compared to those with Stage IV NSCLC harboring epidermal growth factor receptor (EGFR) mutations remains unclear. Methods This study evaluated the efficacy of osimertinib in p...

Description complète

Détails bibliographiques

Auteurs principaux:	Yuko Iida, Hirotsugu Kenmotsu, Keita Mori, Meiko Morita, Motoki Sekikawa, Michitoshi Yabe, Kosei Doshita, Keita Miura, Hiroaki Kodama, Noboru Morikawa, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Yasuhisa Ohde, Yasuhiro Gon, Toshiaki Takahashi
Format:	Artigo
Langue:	Inglês
Publié:	Wiley 2026-04-01
Collection:	Thoracic Cancer
Sujets:	EGFR mutation non–small‐cell lung cancer osimertinib postoperative recurrent
Accès en ligne:	https://doi.org/10.1111/1759-7714.70285
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!